



Food and Drug Administration
Rockville, MD 20857

May 2, 2005

FILE COPY

Mr. Scott L. Cunningham
Covington and Burling
1201 Pennsylvania Avenue, N.W.
Washington, D. C. 20004-2401

Dear Mr. Cunningham:

Your petition on behalf of Wyeth Pharmaceuticals, requesting the Food and Drug Administration to reconsider the Agency's decision to approve the Lachman Consultant Services, Inc. suitability petition to file an abbreviated new drug application for venlafaxine hydrochloride extended-release 37.5 mg, 75 mg, and 150 mg, was received by this office on 4/29/2005. It was assigned docket number 2003P-0159/PRC 1 and it was filed on 4/29/2005. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe
Division of Dockets Management
Office of Management Programs
Office of Management

2003P-0159

ACK 2